Welcome to: Rimonabant Information Source (rimonabant without a prescription)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

This dual effect on smoking cessation and reduced weight gain make rimonabant a promising agent for the treatment of tobacco dependence. "Weight Loss Where It Counts The weight-loss study, more than 1000 moderately obese men and women whose cholesterol and blood fat levels at high risk for diabetes. Half of them had what is known as the metabolic syndrome, a combination of abdominal fat, high blood pressure, high blood-fat levels, low levels of "good" HDL cholesterol and high blood sugar levels. After a year on a diet that restricts daily 600 calorie? more than one in four study participants who inactive placebo pills had lost more than 5% of their body weight. Only one in 10 lost more than 10% of their body weight.

Rimonabant Pricelist

Please wait while we load the price list
"Smoking and obesity are top position of killers in the Western world. This one medication has the power to conflict both conditions, and that explains the enthusiasm." A so-called wonder drug promise to help people give up smoking, loses weight, and slashes their alcohol expenditure. It’s called Acomplia, and it is even being omen as a possible treatment drug addiction. The pill is being developed by the newly merged French company Sanofi Aventis. The drug, which is identified as rimonabant and marketed as Acomplia. Many doctors and political analyst agree. But if Acomplia's early assure ultimately interprets to a profitable drug, then selling it - especially in the huge American market - will stipulate a much larger sales force than Sanofi could have fielded before the takeover.

At that point, those participants who were taking either dosage of rimonabant showed a greater mean weight reduction and a greater mean decrease in waist circumference than participants taking placebo. The drug also decreased the prevalence of the metabolic syndrome. The proportion of subjects who achieved a weight loss of 5% or more was 49% on high-dose rimonabant, 26% on low-dose rimonabant, and 20% on placebo. Individuals who continued taking rimonabant for the second year of the study maintained a mean weight loss of 7. 4 kg, while those who switched to placebo for the second year regained most of the weight they had lost. The same pattern held true for waist size. After 2 years, 40% of the subjects taking high-dose rimonabant achieved a weight loss of 5% or greater, compared with 19% of those taking the placebo.